-- ADS-4101 600 mg achieved higher lacosamide plasma concentration throughout the day and comparable tolerability relative to the approved maximum dose (400 mg) of VIMPAT® (lacosamide) immediate-release tablets, in healthy volunteers --
EMERYVILLE, Calif. , Aug. 08, 2017 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today reported recent achievements and financial results for the second quarter ended June 30, 2017 . "This is a very exciting time for Adamas, as we are potentially at the cusp of transitioning from a
EMERYVILLE, Calif. , Aug. 01, 2017 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today announced that the company will report second quarter 2017 financial results on Tuesday, August 8, 2017 after market close. Subsequently, Adamas' management team will host a conference call and
EMERYVILLE, Calif. , July 10, 2017 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today reported the grant of inducement awards to its new Chief Financial Officer, Alfred G. Merriweather . The compensation committee of the company's board of directors granted Mr.
EMERYVILLE, Calif , June 28, 2017 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today announced the appointment of Alfred G. Merriweather as Chief Financial Officer, reporting to Gregory T. Went , Ph.D., Chairman and Chief Executive Officer, and the retirement of William J.
--Placebo-Controlled Phase 3 Trial Demonstrated that ADS-5102 Significantly Reduced Both Dyskinesia and OFF Time at Six Months in Parkinson's Disease Patients with Levodopa-induced Dyskinesia -- -- New Drug Application for ADS-5102 Currently Under FDA Review with August 24, 2017 PDUFA Date--
-- New subgroup analyses showed that patients previously treated with amantadine IR received benefit of ADS-5102 comparable to patients previously treated with placebo -- -- New Drug Application supporting ADS-5102 for the treatment of levodopa-induced dyskinesia currently under FDA review with
EMERYVILLE, Calif. , June 01, 2017 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today announced that Gregory T. Went , Ph.D., the company's Chairman and Chief Executive Officer, is scheduled to present at two upcoming investor conferences: Jefferies 2017 Global Healthcare
-- Phase 1 results show ADS-4101 is better tolerated in healthy volunteers than equivalent doses of VIMPAT ® (lacosamide) immediate-release tablets -- -- Multi-dose Phase 1b steady state study ongoing, with topline data expected in the third quarter 2017-- EMERYVILLE, Calif.